NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

This was an adaptive trial and was regardless addressed prior to the end of the trial, pursuant to regulation and previous to unblinding. They switched from a more common but fast accumulating endpoint that was a surrogate for survival to Actual Survival, which takes a very long time to accumulate as data. They delayed the end of the trial therefore for a very long time to accumulate REAL data on survival rather than data estimated to possibly predict data.

The use of an external control arm, and crossover to distinguish newly diagnosed versus recurrent Glioblastoma address the issue of confoundment with regard to the drug being so successful that everyone wanted to get the drug in the crossover arm, eliminating the placebo arm.

While the details will no doubt be discussed and any issues that may arise, because they measured a real outcome, survival, the actual benefit will be virtually impossible to ignore. So, you’re incorrect, as always, on a countless array of details. At least you stopped saying some of the false things you usually say to make the outcome a given.